Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.
Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...
Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Courtney Cameron, PharmD, BCACP, about tips for discussing supplement ...
Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.
At the end of the day, GLP-1s can be a powerful tool for achieving your weight loss goals, but only if they're safe and ...
Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...
The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...
The arrival of GLP-1 medications like Ozempic® and Wegovy® has been nothing short of revolutionary for weight loss and diabetes management. These drugs, which include active ingredients like ...
In this video, Mikhail Varshavski, DO, who goes by "Dr. Mike," talks with Christle Guevarra, DO, MS, about her struggle with weight, her journey with GLP-1 drugs, and her career in medicine.
Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...
18hon MSN
Obesity pill race heats up
CNBC's Annika Kim Constantino reports on Eli Lilly after the company said its closely watched obesity pill helped patients ...
The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback